Evaluation of clinical properties of dexmedetomidine in terms of procedural sedation and analgesia

Abstract

Sedation for the short-term but potentially painful procedures is of often used in emergency service. In addition to its ability to provide an ideal sedative regime analgesia and anxiolytics, it must create minimal side effects, protect arterial reflexes, must not cause cardiorespiratory depression and must allow rapid recovery subsequent to the procedure. Objective in sedation is to ensure the conditions in which the patient can conveniently tolerate the process throughout the process. In this study, we efforted to demonstrate that clinical properties of dexmedetomidine an alpha-2 agonist agent which- is used for procedural sedation and analgesia in the light of current literature.

Keywords

• dexmedetomidine, clinical properties, procedural sedation, analgesia

Prosedüral sedasyon ve analjezi açısından dexmedetomidinin klinik özelliklerinin değerlendirilmesi

Abstract

Kısa süreli fakat potansiyel olarak ağrılı prosedürler için sedasyon, sıklıkla acil serviste uygulanmaktadır. İdeal bir sedatif rejimi analjezi ve anksiyoliz sağlaması yanısıra minimal yan etki oluşturmalı, havayolu reflekslerini korumalı, kardiyorespiratuvar depresyona yol açmamalı ve prosedür sonrası hızlı derlenmeye olanak vermelidir. Sedasyondaki amaç, hastanın işlem boyunca işlemi rahat tolere edebileceği şartları sağlamaktır.Biz bu çalışmada, prosedüral sedasyon ve analjezi için kullanılan bir alfa-2 agonist ajan olan dexmedetomidinin klinik özelliklerini güncel literatür ışığında açıklamaya çalıştık.

Keywords

• deksmedetomidin, klinik özellikler, prosedüral sedasyon, analjezi

References

1. Scheinin B, Lindgren L, Randell T, Scheinin H, Scheinin M. Dexmedetomidine attenuates sympathoadrenal responses to tracheal intubation and reduces the need for thiopentone and perioperative fentanyl. Br J Anaesth 1992;68:126–131.
2. Hoy SM, Keating GM. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs. 2011;71(11):1481- 1501.
3. Symington L, Thakore S. A review of the use of propofol for procedural sedation in the emergency department. Emerg Med J. 2006;23(2):89-93.
4. Shehabi Y, Ruettimann U, Adamson H, Innes R, Ickeringill M. Dexmedetomidine infusion for more than 24 hours in critically ill patients: sedative and cardiovascular effects. Intensive Care Med. 2004;30(12):2188-2196.
5. Avitsian R, Lin J, Lotto M, Ebrahim Z. Dexmedetomidine and awake fiberoptic intubation for possible cervical spine myelopathy: a clinical series. J Neurosurg Anesthesiol. 2005 ;17(2):97-99.
6. Bergese SD, Khabiri B, Roberts WD, Howie MB, McSweeney TD, Gerhardt MA. Dexmedetomidine for conscious sedation in difficult awake fiberoptic intubation cases. J Clin Anesth. 2007;19(2):141-144.
7. Multz AS. Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal. Anesth Analg. 2003;96(4):1054-1055.
8. Shukry M, Clyde MC, Kalarickal PL, Ramadhyani U.Does dexmedetomidine prevent emergence delirium in children after sevoflurane-based general anesthesia? Paediatr Anaesth. 2005 ;15(12):1098-1104.

9. Leroy PL, Gorzeman MP, Sury MR. Procedural sedation and analgesia in children by non-anesthesiologists in an emergency department. Minerva Pediatr. 2009;61:193-215.
10. Chrysostomou C, Schmitt CG. Dexmedetomidine: sedation, analgesia and beyond. Expert Opin Drug Metab Toxicol. 2008;4(5):619-627.
11. Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG; SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301(5):489-499.
12. Mato M, Pérez A, Otero J, Torres LM. Dexmedetomidine, a promising drug. Rev Esp Anestesiol Reanim. 2002;49(8):407-420.
13. Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000;90(3):699-705.
14. Venn RM, Grounds RM. Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions. Br J Anaesth. 2001;87(5):684-690.
15. Taiji K. Dexmedetomidine hydrochloride (Precedex), a new sedative in intensive care, its pharmacological characteristics and clinical study result. Nippon Yakurigaku Zasshi. 2004;124 (3):171- 179.
16. Jorden VS, Pousman RM, Sanford MM, Thorborg PA, Hutchens MP. Dexmedetomidine overdose in the perioperative setting. Ann Pharmacother. 2004;38(5):803-807.
17. Tobias JD. Dexmedetomidine and ketamine: An effective alternative for procedural sedation? Pediatr Crit Care Med 2012;13:423–427.
18. Zor F, Ozturk S, Bilgin F, et al: Pain relief during dressing changes of major adult burns: Ideal analgesia combination with ketamine. Burns 2010; 36:501–505.
19. Levänen J, Mäkelä ML, Scheinin H: Dexmedetomidine premedication attenuates ketamine-induced cardiostimulatory effects and postanesthetic delirium. Anesthesiology 1995; 82:1117–1125.
20. Dilek O, Yasemin G, Atci M: Preliminary experience with dexmedetomidine in neonatal anesthesia. J Anesth Clin Pharm 2011; 27:17–22.
21. Jewett J, Phillips WJ. Dexmedetomidine for procedural sedation in the emergency department. Eur J Emerg Med. 2010;17(1):60.
22. Gerlach AT, Murphy CV, Dasta JF. An updated focused review of dexmedetomidine in adults. Ann Pharmacother. 2009;43(12):2064-2074.
23. Mason KP, Prescilla R, Fontaine PJ, Zurakowski D. Pediatric CT sedation: comparison of dexmedetomidine and pentobarbital. AJR Am J Roentgenol. 2011;196(2):W194-198.
24. Koroglu A, Demirbilek S, Teksan H, Sagir O, But AK, Ersoy MO. Sedative, haemodynamic and respiratory effects of dexmedetomidine in children undergoing magnetic resonance imaging examination: preliminary results. Br J Anaesth. 2005;94(6):821-824.
25. Kaygusuz K, Gokce G, Gursoy S,Ayan S,Mimaroglu C, Gultekin Y. A comparison of sedation with dexmedetomidine or propofol during shockwave lithotripsy: a randomized controlled trial. Anesth Analg 2008;106:114 –119.
26. Yuen VM, Irwin MG, Hui TW, Yuen MK, Lee LH. A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. Anesth Analg. 2007;105(2):374- 380.
27. Cheung CW, Ng KF, Liu J, Yuen MY, Ho MH, Irwin MG. Analgesic and sedative effects of intranasal dexmedetomidine in third molar surgery under local anaesthesia. Br J Anaesth. 2011; 107(3):430- 437.
28. Calver L, Isbister GK. Dexmedetomidine in the emergency department: assessing safety and effectiveness in difficult- to-sedate acute behavioural disturbance. Emerg Med J. 2012;29(11):915-918.
29. Phan H, Nahata MC. Clinical uses of dexmedetomidine in pediatric patients. Paediatr Drugs. 2008;10(1):49-69.
30. Su F, Hammer GB. Dexmedetomidine: pediatric pharmacology, clinical uses and safety. Expert Opin Drug Saf. 2011;10(1):55-66.
31. Darrouj J, Puri N, Prince E, Lomonaco A, Spevetz A, Gerber DR. Dexmedetomidine infusion as adjunctive therapy to benzodiazepines for acute alcohol withdrawal. Ann Pharmacother 2008 ;42(11):1703-1705.
32. McMorrow SP, Abramo TJ. Dexmedetomidine sedation: uses in pediatric procedural sedation outside the operating room. Pediatr Emerg Care. 2012;28(3):292-296.
33. Mason KP, Zurakowski D, Zgleszewski S, et al. Incidence and predictors of hypertension during high-dose dexmedetomidine sedation for pediatric MRI. Paediatr Anaesth. 2010;20:516-523.
34. Hoy SM, Keating GM. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs. 2011 ;71(11):1481- 1501.
35. Arnold HM, Hollands JM, Skrupky LP, Mice ST. Optimizing sustained use of sedation in mechanically ventilated patients: focus on safety. Curr Drug Saf. 2010;5(1):6-12.
36. Jakob SM, Ruokonen E, Grounds RM, Sarapohja T, Garratt C, Pocock SJ, Bratty JR, Takala J.Dexmedetomidine for Long- Term Sedation Investigators. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA 2012;307(11):1151- 1160.